Versatility key feature of automated microkeratome
February 15th 2002New Orleans-The automated M2 (Moria) is a simple-to-use, versatile microkeratome that surgeons can rely on to create reproducibly thick flaps, said James J. Salz, MD, at the refractive surgery subspecialty day prior to the American Academy of Ophthalmology annual meeting.
Less demanding famciclovir regimen compares with acyclovir
February 15th 2002Galveston, TX-Three-times-a-day treatment with famciclovir (Famvir, Novartis) was as effective against ophthalmic herpes zoster as five-times-a-day acyclovir (Zovirax, Glaxo Wellcome) in a major international trial, said Stephen K. Tyring, MD, PhD.
Laser, phaco workstation offer efficient cataract removal
February 1st 2002Salt Lake City-The Photon Laser and Phaco Workstation (Paradigm Medical Industries, Salt Lake City) lets surgeons use either laser or ultrasound to remove a cataract, with the ability of switching back and forth between the two modalities.
Power modulation upgrade takes phaco to new level
February 1st 2002New Orleans-WhiteStar, the new power modulation technology for the Sovereign System (Allergan), affords phacoemulsification surgeons improved intraoperative control and optimizes outcomes for patients, with clearer corneas on postoperative day 1, said Lisa Brothers Arbisser, MD, at the annual meeting of the American Academy of Ophthalmology here last fall.
Phacoemulsification technology tailored to nuclear hardness
February 1st 2002Editor's Note: James A. Davison, MD, is associate clinical professor, department of ophthalmology, University of Utah, Salt Lake City. His practice is the Wolfe Clinic, Marshalltown, IA. He discusses his cataract technique with Ophthalmology Times Senior Editor Julia Talsma.
Orbital presentations of giant cell arteritis unusual
January 1st 2002Inflammatory signs of the orbit (e.g., proptosis, chemosis, injection) are rarely the presenting findings in giant cell arteritis (GCA). These patients may be misdiagnosed as having orbital inflammatory pseudotumor when the process is really an underlying orbital ischemic or orbital infarction syndrome.
New technology lessens risk of wound burn during phaco
January 1st 2002Editor's Note: Randall J. Olson, MD, is the John A. Moran presidential professor and chair of ophthalmology, and director of the John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City. He recently spoke with Ophthalmology Times on his approach to cataract surgery.
Future of Cataract Surgery Relies on Refractive Lens Exchange
November 15th 2001Ophthalmologists continue to be concerned about decreasing reimbursement for cataract surgery and the increasing nonreimbursed costs of utilizing new technology. I believe, however, that the future for lens and implant surgery is rosy.
Retinal Prosthesis May do Work of Photoreceptor Cells
November 15th 2001Houston-An artificial retina could be the answer for an estimated 1 million Americans with retinal blindness by conditions such as retinitis pigmentosa and age-related macular degeneration, said Alex Ignatiev, PhD, professor of physics, chemistry, and electrical and computer engineering at the University of Houston.
Purite May be Gentler Preservative for Lubrication Solutions
November 1st 2001Almost all ophthalmic medications contain preservatives, which inhibit bacterial growth. The use of preservatives allows for the use of multidose bottles, which are the most cost-effective and user-friendly packaging for ophthalmic medications. However, some of the preservatives present in commonly used eye drops today have been shown to be disruptive to the cornea surface.1-5